Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT03795142

A First-time-in-human Study of BGB149

A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BGB149 Following Single Dose Administration in Healthy Subjects

Sponsor: BerGenBio ASA

Conditions Healthy Volunteers

Interventions BGB149 Placebo

Updated 6 times since 2019 Last updated: Mar 1, 2022 Started: Dec 19, 2018 Primary completion: Oct 31, 2019 Completion: Oct 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by BerGenBio ASA and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Apr 2022 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Apr 2022 [monthly]

Completed EARLY_PHASE1
Jun 2020 — Jan 2021 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Feb 2019 — Jun 2020 [monthly]

Recruiting EARLY_PHASE1

First recorded

Dec 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BerGenBio ASA

Data source: BerGenBio ASA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom